Quale sarebbe il prezzo per Hillstream BioPharma, Inc. (HILS)

Il prezzo per Hillstream BioPharma, Inc. (HILS) è $0.181

Qual è la capitalizzazione di mercato per Hillstream BioPharma, Inc. (HILS)

La capitalizzazione di mercato per Hillstream BioPharma, Inc. (HILS) è $2.03M

Hillstream BioPharma, Inc. (HILS) Rapporto P/B

Hillstream BioPharma, Inc. is a pre-clinical stage biotechnology firm committed to creating groundbreaking therapeutic options. Its core mission is to exploit ferroptosis, an anti-cancer pathway that initiates iron-mediated cell death (IMCD), specifically to address cancers that are resistant to conventional treatments. The company's developmental pipeline features several key candidates: HSB-1216: An IMCD inducer currently under development for solid tumor indications. HSB-888: An IMCD inducer incorporating an anthracycline analogue, delivered via a dual Quatramer system, also aimed at solid tumors. HSB-510: A targeted bifunctional inhibitory compound, encapsulated within the Quatramer delivery system, which demonstrates remarkable potency (single-digit nanomolar IC50) against both PI3K-delta and HDAC6, targets recognized for their role in downregulating cellular processes. HSB-114: An immunotherapeutic agent that leverages the proprietary Quatramer technology to precisely deliver the tumor necrosis factor-alpha gene into cancer cells. Established in 2017, the company's operations are based in Bridgewater, New Jersey.

Anno	Rapporto P/B	Cambia
Non abbastanza dati per le date fornite.

Anno

Rapporto P/B

Cambia

Non abbastanza dati per le date fornite.

Azienda	Rapporto P/B	Differenza del rapporto P/B	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	3.4612	-	BE

Azienda

Rapporto P/B

Differenza del rapporto P/B

Il paese